P erturbations in very-low-density lipoprotein (VLDL) production contribute to the pathogenesis of hyperlipidemia, hepatic steatosis, and insulin resistance. A central pathophysiological feature of obesity and type 2 diabetes mellitus is hyperlipidemia characterized by overproduction of VLDL, formation of atherogenic small dense LDL, and decreased high-density lipoprotein cholesterol which is associated with increased cardiovascular risk.
P erturbations in very-low-density lipoprotein (VLDL) production contribute to the pathogenesis of hyperlipidemia, hepatic steatosis, and insulin resistance. A central pathophysiological feature of obesity and type 2 diabetes mellitus is hyperlipidemia characterized by overproduction of VLDL, formation of atherogenic small dense LDL, and decreased high-density lipoprotein cholesterol which is associated with increased cardiovascular risk. 1 Thus, seeking therapeutic approaches to prevent and correct the abnormal lipoprotein profile is warranted in patients with insulin resistance and type 2 diabetes mellitus.
The incretin hormone glucagon-like peptide-1 (GLP-1) is secreted by enteroendocrine L cells in response to the stimulus from ingested nutrients, primarily glucose and monounsaturated fatty acids. GLP-1 regulates energy metabolism by promoting glucose-dependent insulin secretion, improving peripheral insulin sensitivity, inhibiting glucagon secretion, slowing gastric emptying, and enhancing satiety. [2] [3] [4] [5] [6] More recently, GLP-1 has been implicated in improving dyslipidemia in rodent models and diabetic patients by reducing lipoprotein production [7] [8] [9] and was found to prevent development of atherosclerotic lesions in apoE (apolipoprotein E) knock-out mice. 10, 11 In the liver, GLP-1 receptor (GLP-1R) agonist has been shown to enhance hepatic β-oxidation thereby reducing lipid stores in high-fat-fed mice, which makes GLP-1 a potential therapy in the treatment of hepatic steatosis. 4, 12 Hepatic lipid metabolism has been recently shown to be regulated by central signaling pathways. 13, 14 Interestingly, GLP-1 has been shown to cross the blood-brain barrier and is also synthesized in the brain as a neuropeptide where it contributes to central regulation of metabolic and cardiovascular functions. 15, 16 In addition to hormonal regulation, nutrient sensing by the brain has also been shown to modulate peripheral lipid metabolism. This is highlighted in a study where selectively increased glucose levels in the hypothalamus of mice downregulated circulating triglyceride levels by decreasing VLDL secretion. This action was mediated by brain-liver vagal signals and involved inhibition of hepatic SCD-1 (stearoyl-CoA desaturase-1).
14 SCD-1 participates in the de novo synthesis of monounsaturated fatty acid from saturated fatty acids. One of the major metabolites of this reaction is oleic acid which is the major monounsaturated fatty acid in phospholipids, triglyceride, cholesterol esters, and diacylglycerol. Simultaneous deletion of SCD-1 in liver and adipose tissues reportedly reduced monounsaturated fatty acid levels and improved glucose tolerance. 17, 18 This evidence suggests that hepatic SCD-1 may be an effective target in modulating hepatic steatosis.
The vagus nerve is the main parasympathetic nervous system, which consists of both afferent and efferent vagal signaling, and plays an important role in the regulation of feeding behavior and metabolic homeostasis. Vagal activity has been shown to be increased by both portal or jejunal infusion of lipids, 19 highlighting a vagal response to peripheral lipid sensing. Additional evidence indicates that afferent vagal fibers of the hepatic branch mediate glucocorticoid-induced insulin resistance and hypertension by upregulating hepatic PPARα (peroxisome proliferator-activated receptor alpha) activity. 20 Although these studies implicate the importance of afferent or efferent vagal nerve signals in conveying the nerve signaling from the central nervous system, clinically, complete disruption of abdominal vagus nerve fibers which block both afferent and efferent vagal nerve signals have also consistently abrogated weight gain or induced weight loss in obese subjects. 17 A defining mechanism to explain the effects of truncal vagotomy on energy balance has yet to be determined. In this study, our objective was to determine how a gut-liver regulatory circuit regulates hepatic lipid metabolism and insulin sensitivity using a subdiaphragmatic vagotomy mouse model under various nutritional conditions, including fast, fed, acute fat load to mimic a postprandial scenario and a high-fat diet (HFD).
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Disrupted Subdiaphragmatic Vagal Signaling Decreases Circulating Triglyceride and Protects Mice From Acute Fat Load-Induced Overproduction of Triglyceride-Rich Lipoproteins
To determine the effect of subdiaphragmatic vagotomy on circulating lipid metabolism, we first examined fasted and fed state (ad libitum) circulating lipid levels. Body weight and food intake were comparable between sham and vagotomized mice at the age of 12 to 14 weeks and fed a regular chow diet ( Figure  IA and IB in the online-only Data Supplement). In vagotomized mice, plasma triglyceride content was significantly reduced at both fasted and fed states when compared with the sham controls ( Figure 1A ). No significant alteration was observed in plasma cholesterol levels ( Figure 1A) . To further identify which subclass of lipoprotein was affected by vagotomy, fast protein liquid chromatography was applied to separate the various densities of lipoprotein particles. Determination of lipid contents in each fraction demonstrated that VLDL-triglyceride content was significantly lower (3-fold) in vagotomized mice with no changes in LDL-associated or high-density lipoprotein-associated triglyceride ( Figure 1B, left) . Cholesterol content in all fractions was comparable between vagotomized and sham mice ( Figure 1B, right) , suggesting that vagotomy mainly regulates VLDL-triglyceride metabolism. To investigate the impact of vagotomy on postprandial hyperlipidemia, mice were given an acute oral fat load of olive oil (200 μL) and plasma lipids were measured 1 hour postprandially. Determination of plasma lipids revealed that postprandial plasma triglyceride was significantly lower in vagotomized mice with no significant changes in plasma cholesterol ( Figure 1C ). The reduced triglyceride was accompanied by less secretion of apoB48, the structural protein component of intestinal chylomicrons ( Figure 1D ), and was maintained in primary hepatocytes isolated from vagotomized mice and cultured ex vivo for 48 hours ( Figure IC in the online-only Data Supplement). This suggests that vagotomy inhibits the secretion of triglyceride-rich lipoproteins thereby leading to a decrease in postprandial lipemia.
Subdiaphragmatic Vagotomy Prevents HFDInduced Obesity and VLDL Overproduction
To further investigate the impact of vagotomy on HFD-induced obesity and hyperlipidemia, 2 groups of sham and vagotomized mice were subjected to an HFD for 22 weeks. The HFD induced significant body weight gain in the sham mice beginning at week 12 and continued to the end of the feeding trial (22 weeks). In contrast, there was no significant body weight change in vagotomized mice during the feeding trial (Figure 2A and 2B). Caloric intake was comparable between sham and vagotomized mice ( Figure IIA in the online-only Data Supplement). Plasma triglyceride at weeks 0, 12, 20, and 22 was significantly decreased in vagotomized mice ( Figure 2C ) with no changes in plasma cholesterol ( Figure 2C ). To determine whether the reduced plasma triglycerides resulted from decreased secretion of hepatic VLDL or increased lipid clearance, we subjected the mice to an in vivo VLDL production assay. Fasted mice received poloxamer (500 mg/kg) through intraperitoneal injection to inhibit the activity of lipoprotein lipase and prevent hydrolysis of circulating VLDL particles. Plasma triglyceride levels were significantly decreased in the vagotomized mice at all time points, 0, 1, 2, and 3 hours ( Figure 2D) ; however, no significant differences were observed in plasma cholesterol ( Figure 2D ). To further determine whether there was a delay in postprandial plasma lipid response in the vagotomized mice, we extended the experimental time course to 6 hours postpoloxamer treatment and found that plasma triglycerides in the vagotomized mice were markedly lower at all time points 
Vagotomy Inhibits Hepatic De Novo Lipid Synthesis and Prevents HFD-Induced Hepatic Steatosis via Modulation of Lipogenic Gene Expression and Lipid Excretion
The improved plasma lipid profile and reduced VLDL secretion in the vagotomized HFD-fed mice led to investigating mechanistic changes in hepatic lipid metabolism. To determine whether vagotomized mice have increased activity levels, we monitored the activity counts of the vagotomy and sham mice in metabolic cages for 60 hours. No significant differences were observed in the average activity counts between these 2 groups ( Figure Figure 3C ). This observation was further corroborated by quantitatively examining hepatic lipid content. As shown in Figure 3D , hepatic triglyceride was significantly reduced in HFD-fed vagotomized mice compared with sham controls, with no significant differences in cholesterol ( Figure 3D ). The availability of lipid substrates (eg, triglyceride and cholesterol) in hepatocytes is important for the proper lipidation and stabilization of apoB100 during the assembly of VLDL. Lack of lipids will result in degradation of apoB100 and reduced secretion of VLDL. 21, 22 Consistently, we found that there was less apoB100 protein in the hepatocytes of vagotomized mice compared with the sham controls ( Figure 3E ). apoE and MTP (microsomal triglyceride transfer protein) were not affected by vagotomy ( Figure 3E ). Furthermore, fecal triglyceride contents were found to be higher in the vagotomized mice on both chow and HFD ( Figure IIIC in the online-only Data Supplement), indicating an increased excretion of lipid. Fecal cholesterol content was higher in both vagotomized and sham mice on exposure to high-fat feeding ( Figure IIIC in the online-only Data Supplement). Together, these results indicate that vagotomy inhibits hepatic de novo fatty acid synthesis and enhances fecal lipid excretion, leading to reduced lipid synthesis and VLDL assembly in hepatocytes, which protects mice from HFD-induced hepatic steatosis and hyperlipidemia. 
Vagotomy Improves Systemic Glucose Tolerance and Enhances Hepatic Insulin Sensitivity in HFD-Induced Insulin Resistance
Significant improvement of lipid profiles in vagotomized mice prompted analysis of insulin sensitivity and glucose tolerance. After an oral glucose tolerance test, vagotomy was found to improve glucose tolerance in chow-fed mice as indicated by significantly lower blood glucose levels at 15, 60, and 90 minutes postglucose administration ( Figure 4A ). Similar effects were observed in HFD-fed mice given that vagotomy reduced glucose levels at 30, 60, and 90 minutes postglucose administration, indicating improved glucose tolerance ( Figure 4B) . High-fat feeding induced glucose intolerance in sham mice, indicated by the much higher blood glucose levels at all time points within the 90 minutes time course postglucose delivery (compared Figure 4A with Figure 4B ). However, this glucose intolerance was ameliorated in HFD-fed vagotomized mice (compared Figure 4A with Figure 4B ). Further examination of insulin signaling molecules in the liver by immunoblotting analysis showed that protein expression of the hepatic insulin receptor was significantly increased in vagotomized mice compared with sham controls (Figure 4C ). Treating mice with insulin through portal vein injection induced much stronger activation of AKT, a key molecule in the insulin signaling pathway (Figure 4D ), suggesting enhanced hepatic insulin sensitivity by vagotomy. 
Upregulation of GLP-1 by Vagotomy Contributes to Suppression of Hepatic De Novo Lipogenesis
The incretin hormone GLP-1 is secreted by intestinal L cells and has been implicated in improving dyslipidemia by reducing lipoprotein production. [7] [8] [9] 12 In addition, the GLP-1R has been found to be expressed on the vessel wall of the portal vein near the liver hilus, on enteric neurons, vagal, and dorsal root ganglia. 7, 23 To determine whether GLP-1 may play a role in inhibiting hepatic lipid synthesis in vagotomized mice, we next assessed circulating GLP-1 levels and found that plasma GLP-1 was significantly elevated in vagotomized mice compared with sham controls in both fasted and fed (ad libitum) states, with a more profound increase in the fed state ( Figure 5A ). Administration of a fat load (200 μL olive oil) through oral gavage, inducing a postprandial state, further increased plasma GLP-1 levels in vagotomized mice by 4-and 3-fold compared with fasted and fed states, respectively ( Figure 5A and 5B). Interestingly, fasting plasma insulin levels were significantly lower in vagotomized mice compared with sham ( Figure IV in the online-only Data Supplement). These results indicate that, in the absence of vagal signaling, secretion of GLP-1 was significantly enhanced in response to nutrient ingestion.
To investigate whether the GLP-1R signaling is capable of inhibiting hepatic lipid synthesis, we treated McA (McA-RH7777) cells, a rat hepatoma cell line, with palmitic acid (50 μmol/L) in the presence or absence of a GLP-1R agonist, exendin-4 (100 nmol/L), for 48 hours. Palmitic acid treatment significantly enhanced mRNA expression of SREBP-1c, a master transcription factor in hepatic de novo lipid synthesis, and its downstream target enzymes that are involved in fatty acid synthesis, including FASN, SCD-1, and ACC (acetyl-CoA carboxylase; Figure 6A ). Coincubation with exendin-4 inhibited expression of these lipogenic genes ( Figure 6A ). Treating mouse primary hepatocytes with palmitic acid (50 μmol/L) for 48 hours significantly enhanced triglyceride secretion from hepatocytes, whereas cotreatment of palmitic acid with exendin-4 (100 nmol/L) reduced the secreted triglyceride to a level similar to the control ( Figure 6B ). No significant change was observed in the secreted cholesterol ( Figure 6B ). These results suggested that exendin-4 is capable of inhibiting triglyceride synthesis. Thus, the upregulated GLP-1 observed in vagotomized mice may, at least partially, be responsible for the lower plasma and hepatic triglyceride contents in vagotomized mice.
Discussion
In this study, our goal was to delineate the underlying mechanism of subdiaphragmatic vagotomy in preventing obesity, hyperlipidemia, and insulin resistance. We demonstrated that complete disruption of both afferent and efferent vagal fibers resulted in significant decreases of fasting and postprandial plasma triglyceride levels, which was further associated with reduced VLDL assembly and secretion as well as an improvement of obesity, hepatic steatosis, and insulin resistance induced by an HFD. We further demonstrated that significant upregulation of secreted GLP-1 in the blood circulation by vagotomy may be responsible for the inhibition of hepatic fatty acid synthesis and the subsequently reduced VLDL biogenesis in the HFD mice. Increased excretion of dietary lipids from feces may further contribute to the prevention of obesity and hyperlipidemia induced by HFD. These findings provide novel insights for the application of vagotomy or suppressed parasympathetic signaling in the clinical treatment of patients with obesity and diabetes mellitus.
Emerging evidence has demonstrated that the vagus nerve suppresses systemic inflammation, 24 modulates central nervous system responses to glucose and fatty acids, 14, 25, 26 and regulates insulin sensitivity 27 and hypertension. 20 These reported studies mainly focused on the association between either the efferent or afferent fibers of vagal nerve with the central nervous system. In rodents, hypothalamic infusion of fatty acids, oleic acid, or glucose suppresses hepatic glucose production or VLDL secretion through mechanisms involving descending vagal signaling. 7, 14, 20, 25, 26 Afferent fibers of the vagus nerve were found to modulate hepatic PPARα expression which disturbed blood pressure and glucose homeostasis in response to glucocorticoids. Moreover, selective hepatic branch vagotomy was found to ameliorate hyperglycemia, hepatic insulin resistance, and blood pressure. 20 Because there was little direct innervation of hepatocytes by the vagus nerve, the authors postulated that metabolic responses involved a regulatory compartment of hepatocytes located near the portal triads may be the mechanism for this regulation. That was induction of PPARα-dependent genes in hepatocytes could increase extracellular metabolites in the portal triads, resulting in vagal afferent signals that were translated by the brain to exert its peripheral effects on glucose metabolism and hypertension development. In this study, we used a complete subdiaphragmatic vagotomized mouse model in which both afferent and efferent vagal nerve fibers were disrupted. This model blocked the central nervous system regulation on the abdominal vagus nerve activity and thus allowed us to investigate the intrinsic gut-liver regulatory circuit locally. Our study revealed that significant upregulation of the incretin GLP-1 may contribute to the markedly lower plasma and liver triglyceride levels in the HFD-fed vagotomized mice via downregulation of genes involved in free fatty acid synthesis, including SREBP-1c, SCD-1, and FASN. Because sufficient lipid substrates in hepatocytes are essential for the proper lipidation and stabilization of apoB100, the major structural protein component of VLDL particles, reduced hepatic lipid synthesis in vagotomized mice resulted in less availability of lipid substrates for VLDL assembly, which, in turn, led to the reduced secretion of VLDL particles and prevented hyperlipidemia induced by HFD.
It is well accepted that GLP-1 signals through a known GLP-1R that was initially cloned from a library of pancreatic islet cells but is also expressed in the stomach, lung, brain, and various other tissues. 28, 29 Whether GLP-1R is expressed on hepatocytes has remained controversial. 30 Several studies suggest that GLP-1 can signal through a neural circuit originating in the hepatic-portal area. Nakabayashi et al 31 demonstrated a neural reflex in an in situ rat model whereby hepatic vagal afferent and vagal efferent activities to the pancreas were stimulated by intraportal injection of GLP-1. Consistent with this finding, infusion of GLP-1 and glucose intraportally caused an increase in glucose-stimulated insulin secretion that was attenuated by neural blockade. 32 Studies in dogs further support a portal action of GLP-1 in promoting glucose metabolism. 33, 34 More recently, Vahl et al 29 were able to isolate GLP-1R mRNA from the nodose ganglia and nerve terminals innervating the portal vein. Using a fluorescent reporter that revealed the expression GLP-1R in mice provided further direct evidence to support this notion. 23 This study found that hepatocytes were not GLP-1R fluorescent, but fluorescent fibers were observed in the wall of the portal vein near the liver hilus, which is consistent with the report from Vahl et al. 23, 29 This group further demonstrated that GLP-1R fluorescent neuronal fibers and cell bodies were also scattered in the small intestine and colon, but not on the intestinal epithelial layer. GLP-1R fluorescent fibers were observed in the mucosa, in some cases relatively close to L cells. 29 These studies supported the notion that effects of GLP-1 may be mediated by a hepatic-portal neural network. Therefore, it is plausible to speculate that, in the complete subdiaphragmatic vagotomized mice used in this study, the elevated GLP-1 binds to the GLP-1Rs on neuronal fibers and cell bodies in the mucosa of the small intestine and the vessel wall of the portal vein to assemble as a local regulatory circuit that regulates hepatic lipogenic gene expression and the subsequent lipid and lipoprotein metabolism as evidence provided in the current study. Moreover, in the ex vivo hepatic primary cell culture study, we further observed that treatment with a GLP-1R agonist, exendin-4, for 48 hours inhibited lipid synthesis in hepatocytes. This observation may suggest that there is unidentified GLP-1R on hepatocytes. Alternatively, GLP-1 or exendin-4 may share common receptors with other metabolic hormones, such as insulin receptor. Future studies to clarify the interaction between GLP-1 and hepatocytes and their association with the vagal signals could yield new approaches for treatment of insulin resistance and the associated lipid disorders. 
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